Spinraza
nusinersen
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Spinraza. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Spinraza.
For practical information about using Spinraza, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Spinraza : EPAR - Summary for the public (PDF/78.3 KB)
First published: 21/06/2017
Last updated: 11/01/2018 -
-
List item
Spinraza : EPAR - Risk-management-plan summary (PDF/623.24 KB)
First published: 09/10/2019
Authorisation details
Product details | |
---|---|
Name |
Spinraza
|
Agency product number |
EMEA/H/C/004312
|
Active substance |
nusinersen sodium
|
International non-proprietary name (INN) or common name |
nusinersen
|
Therapeutic area (MeSH) |
Muscular Atrophy, Spinal
|
Anatomical therapeutic chemical (ATC) code |
M09
|
Accelerated assessment |
This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment. |
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Biogen Netherlands B.V.
|
Revision |
11
|
Date of issue of marketing authorisation valid throughout the European Union |
30/05/2017
|
Contact address |
Product information
10/02/2021 Spinraza - EMEA/H/C/004312 - IAIN/0022/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Other nervous system drugs
Therapeutic indication
Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.